Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

TNFAIP3 activates MYD88-L265P. 2 / 2

| 2

➶

reach

"The lack of any measurable effect of CD79B in these assays contrasts with our previous findings, in which loss-of-function mutations in Tnfaip3 (A20) blocked MYD88 L265P -induced down-regulation of CD23, CD25, CD86, and CD95."

28701369

➶

reach

"Overall, these results suggest that MYD88 L265P signaling can be enhanced by a second genetic alteration in TNFAIP3 and highlights a potential opportunity for therapeutic targeting."

30301877

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...